NASDAQ$CCRN
Cross Country Healthcare Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Second quarter results reflected continued strong performance driven by leveraging technology and deep relationships to efficiently place professionals across the healthcare continuum.
Cross Country Healthcare announced strong second quarter 2022 results with revenue increasing 127% year-over-year to $753.6 million and net income attributable to common stockholders increasing 358% year-over-year to $52.9 million.
- Revenue and Adjusted EBITDA exceeded guidance ranges
- Record number of professionals on assignment
- Double-digit year-over-year growth across all lines of business
- Adjusted EBITDA margin of 11.1%
Headline financials
Revenue & EPS history
Cross Country Healthcare · Revenue · Quarterly
$754M
Revenue by segment
Cross Country Healthcare · $754M total across 2 segments · Q2 2022
- Nurse and Allied Staffing$731M+131.3%97.1%
- Physician Staffing$22.1M+41.4%2.9%
Forward guidance
The guidance below applies to management’s expectations for the third quarter of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
-2.7%
Avg return
Earnings day
-1.5%
Avg return
5 days after
+0.5%
Avg return
30 days after
44%
28 / 64 earnings
Positive
+24.6%
Q3 2021
Best reaction
-33.6%
Q2 2010
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.8% | +0.4% | +0.8% | |
| Q4 2025 | +8.2% | +7.9% | +0.5% | |
| Q3 2025 | -14.1% | -7.2% | -32.9% | |
| Q1 2025 | +0.4% | +0.8% | -6.7% | |
| Q4 2024 | +0.3% | -6.0% | -13.9% | |
| Q3 2024 | +7.2% | -6.1% | +57.9% | |
| Q2 2024 | -2.7% | -8.2% | -17.3% | |
| Q1 2024 | -4.9% | -9.0% | -14.1% | |
| Q4 2023 | -2.7% | -0.3% | +5.7% | |
| Q3 2023 | -14.0% | -19.0% | -10.7% | |
| Q2 2023 | -14.7% | -14.0% | -3.8% | |
| Q1 2023 | +5.1% | +9.9% | +26.1% | |
| Q4 2022 | -5.6% | +3.2% | -13.2% | |
| Q3 2022 | -2.5% | -11.3% | -2.8% | |
| Q2 2022 | -13.7% | -14.1% | -7.6% | |
| Q1 2022 | -2.6% | -7.1% | +0.9% | |
| Q4 2021 | -1.5% | +6.6% | +2.4% | |
| Q3 2021 | +24.6% | +18.0% | +21.1% | |
| Q2 2021 | +23.0% | +14.6% | +29.7% | |
| Q1 2021 | +16.5% | +24.0% | +17.4% | |
| Q4 2020 | +18.9% | +24.6% | +33.8% | |
| Q3 2020 | -5.0% | -3.0% | +9.3% | |
| Q2 2020 | +9.6% | +4.7% | +1.6% | |
| Q1 2020 | -4.8% | -2.0% | +7.6% | |
| Q4 2019 | +0.4% | -12.2% | -27.7% | |
| Q3 2019 | +14.2% | +16.9% | +10.9% | |
| Q2 2019 | -0.8% | -5.5% | +5.6% | |
| Q1 2019 | +4.7% | +18.7% | +0.9% | |
| Q4 2018 | -3.6% | -11.6% | -22.5% | |
| Q3 2018 | +7.8% | +3.4% | +2.7% | |
| Q2 2018 | -30.9% | -26.0% | -14.7% | |
| Q1 2018 | -16.7% | -11.0% | -4.3% | |
| Q4 2017 | -18.8% | -13.6% | -15.8% | |
| Q3 2017 | -9.6% | -13.8% | -2.6% | |
| Q2 2017 | +3.1% | +1.2% | +2.5% | |
| Q1 2017 | -13.0% | -15.1% | -16.7% | |
| Q4 2016 | +3.4% | -5.3% | -7.2% | |
| Q3 2016 | +22.9% | +24.3% | +31.7% | |
| Q2 2016 | -11.5% | -17.0% | -14.2% | |
| Q1 2016 | +10.0% | — | — | |
| Q4 2015 | -21.9% | — | — | |
| Q3 2015 | +9.5% | — | — | |
| Q2 2015 | +10.1% | — | — | |
| Q1 2015 | -4.6% | — | — | |
| Q4 2014 | -9.6% | — | — | |
| Q3 2014 | -0.5% | — | — | |
| Q2 2014 | +1.8% | — | — | |
| Q1 2014 | -14.3% | — | — | |
| Q4 2013 | -22.3% | — | — | |
| Q3 2013 | +3.1% | — | — | |
| Q2 2013 | -3.3% | — | — | |
| Q1 2013 | +0.4% | — | — | |
| Q4 2009 | -5.5% | — | — | |
| Q3 2012 | -0.9% | — | — | |
| Q2 2012 | -5.5% | — | — | |
| Q1 2011 | -3.1% | — | — | |
| Q1 2012 | +11.8% | — | — | |
| Q4 2011 | +0.8% | — | — | |
| Q3 2010 | +2.5% | — | — | |
| Q3 2011 | +2.5% | — | — | |
| Q2 2011 | -33.6% | — | — | |
| Q4 2010 | -33.6% | — | — | |
| Q2 2010 | -33.6% | — | — | |
| Q1 2010 | -7.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro